In
HIV and ID Observations, Dr. Paul Sax discusses the good news about long-acting cabotegravir-rilpivirine.
Long-acting cabotegravir-rilpivirine is the biggest advance in HIV therapeutics in years, but it's also creating quite the challenge for ID and HIV clinicians, says Dr. Paul Sax in the latest HIV and ID Observations. In the first of two posts, he relays the good news about this groundbreaking treatment.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.Want to see more from NEJM Journal Watch? Register here.